Abemaxen 150 MG (Abemaciclib INN)
Product Name : Abemaxen
Generic Name : Abemaciclib INN
Formulation : Tablet
Available Pack Size : 60’s Pot
Available Strengths : 150mg
Registrations :
Product Information
Abemaxen (Abemaciclib) 150mg is an oral CDK4 and CDK6 inhibitor used in the treatment of hormone receptor-positive, HER2-negative breast cancer, both as adjuvant therapy for node-positive early breast cancer at high risk of recurrence and in advanced or metastatic disease. It works by blocking cyclin-dependent kinases 4 and 6, preventing phosphorylation of the retinoblastoma protein and arresting the cancer cell cycle before it can pass from the G1 phase into DNA replication. Abemaxen is taken continuously twice daily with no treatment break, alongside endocrine therapy. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Abemaxen (Abemaciclib) 150mg
| Brand Name | Abemaxen 150 (Abemaciclib) |
| Generic Name | Abemaciclib INN |
| Drug Class | CDK4 and CDK6 Inhibitor (Cyclin-Dependent Kinase Inhibitor, Targeted Anticancer Therapy) |
| Available Strengths | 150mg (this listing) and 200mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 60 Tablets per Pot (a complete 30-day supply at 150mg twice daily) |
| Primary Indication | Hormone Receptor-Positive, HER2-Negative Breast Cancer (adjuvant early-stage and advanced or metastatic disease) |
| Companion Therapy | Endocrine therapy: tamoxifen or an aromatase inhibitor (adjuvant setting), an aromatase inhibitor (first-line advanced), or fulvestrant (after endocrine progression). Monotherapy in selected pre-treated metastatic patients. |
| Dosing Schedule | Continuous twice-daily dosing with no scheduled treatment break, unlike other CDK4/6 inhibitors that require a 7-day rest each cycle |
| Regulatory Approvals | Abemaciclib is USFDA approved for adjuvant treatment of HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence, and for HR-positive, HER2-negative advanced or metastatic breast cancer. Also approved by the EMA. |
| Originator Brand | Verzenio / Verzenios by Eli Lilly |
| Manufacturer | Everest Pharmaceuticals Ltd., Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration Status | Manufacturer-listed oncology product. Contact Mediaid Pharmacy for current registration and export documentation for your country. |
| Storage Conditions | Store below 30 degrees Celsius in a dry place, protected from light and moisture. Keep tablets in the original pot with the closure tightly sealed. Keep out of the reach of children. |
How Abemaxen (Abemaciclib) Works
Abemaxen contains Abemaciclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These enzymes act as the gatekeepers of cell division. When CDK4 and CDK6 pair with cyclin D, they phosphorylate the retinoblastoma protein (Rb), releasing the brake that holds a cell in the resting G1 phase and allowing it to enter S phase and begin copying its DNA.
In hormone receptor-positive breast cancer, oestrogen signalling drives cyclin D production, which keeps the CDK4/6 pathway permanently switched on and the cell cycle running unchecked. By inhibiting CDK4 and CDK6, Abemaciclib prevents Rb phosphorylation and arrests the tumour cell in G1, stopping proliferation at its origin. This is why the medicine is given together with endocrine therapy: the two act on the same growth axis at different points, and blocking both is substantially more effective than blocking either alone.
Abemaciclib is more selective for CDK4 than CDK6 than other agents in its class. This has two practical consequences that shape how it is used: it produces less severe bone marrow suppression, which is why it can be dosed continuously twice daily without a scheduled treatment break, and it is the only CDK4/6 inhibitor with sufficient single-agent activity to be approved as monotherapy in pre-treated metastatic disease.
Indications for Abemaxen (Abemaciclib)
Abemaxen (Abemaciclib) is indicated for the following conditions, in each case in hormone receptor-positive, HER2-negative breast cancer:
|
Adjuvant Early Breast Cancer In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. Treatment continues for two years. This indication, based on the monarchE trial, is given after surgery with the aim of preventing the cancer from returning. |
First-Line Advanced or Metastatic Disease In combination with an aromatase inhibitor as initial endocrine-based therapy for HR-positive, HER2-negative advanced or metastatic breast cancer, based on the MONARCH 3 trial. Treatment continues until disease progression or unacceptable toxicity. |
|
After Progression on Endocrine Therapy In combination with fulvestrant for adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer whose disease has progressed on or after prior endocrine therapy, based on the MONARCH 2 trial. Pre-menopausal and peri-menopausal women receiving this combination also require ovarian suppression with a GnRH agonist. |
Monotherapy in Pre-Treated Metastatic Disease As a single agent for adults with HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed following endocrine therapy and prior chemotherapy in the metastatic setting. Note that monotherapy is dosed at 200mg twice daily and requires the Abemaxen 200mg strength. |
Benefits of Abemaxen (Abemaciclib) 150mg
|
Reduces Risk of Recurrence In the adjuvant setting, adding Abemaciclib to endocrine therapy for two years significantly improves invasive disease-free survival in node-positive, high-risk early breast cancer. This is treatment aimed at cure, not just control, for women who have completed surgery. |
No Treatment Break Required Abemaxen is taken continuously twice daily with no scheduled rest week, unlike other CDK4/6 inhibitors which require a 7-day break each cycle. This gives uninterrupted pathway suppression and a simpler routine with no calendar tracking for patients to manage. |
Exact 30-Day Pack At two tablets daily, one 60-tablet pot is precisely one month of treatment. Ordering, budgeting, and supply planning are straightforward, with no part-packs or carry-over quantities to track between shipments. |
|
Lower Rate of Severe Neutropenia Greater selectivity for CDK4 over CDK6 means less suppression of the bone marrow than is typical for this drug class. Severe neutropenia is less frequent, which is what makes continuous dosing feasible. |
Affordable Alternative to Verzenio Abemaxen contains the same active molecule as Verzenio by Eli Lilly at a small fraction of the originator price. For adjuvant therapy in particular, where treatment runs for a full two years, the cost difference over the complete course is substantial. |
GMP-Certified Oncology Manufacturing Produced by Everest Pharmaceuticals Ltd. in dedicated oncology facilities operating to current Good Manufacturing Practice standards, with batch-level analytical release testing for identity, assay, dissolution, and impurity profile. |
How to Take Abemaxen (Abemaciclib)
Route: Oral. Swallow tablets whole with water. Do not chew, crush, or split the tablets, and do not take any tablet that is broken or damaged.
Standard dose with endocrine therapy: 150mg twice daily, which is one 150mg tablet in the morning and one in the evening, taken at approximately the same times each day with a minimum separation of about 6 hours between doses.
Duration in early breast cancer: Continue for a total of 2 years, or until disease recurrence or unacceptable toxicity, alongside the prescribed endocrine therapy.
Duration in advanced or metastatic disease: Continue until disease progression or unacceptable toxicity.
Monotherapy dose: 200mg twice daily. This requires the Abemaxen 200mg strength and is used only in the pre-treated metastatic setting.
With food: May be taken with or without food. Avoid grapefruit and grapefruit juice throughout treatment.
Missed dose: Do not take a replacement dose. Skip the missed dose and take the next one at its usual scheduled time. Do not take two doses together.
If vomiting occurs: Do not take an additional dose. Resume at the next scheduled dose.
Renal impairment: No dose adjustment is required for mild or moderate renal impairment. Data are limited in severe impairment.
Hepatic impairment: No dose adjustment is required for mild or moderate hepatic impairment (Child-Pugh A or B). In severe hepatic impairment (Child-Pugh C), the dosing frequency is reduced to once daily.
Pack Supply Calculation for Ordering
Abemaxen 150mg, 60 tablets per pot: 2 tablets per day at 150mg twice daily. One pot = exactly 30 days. A three-month supply is 3 pots; a six-month supply is 6 pots.
Full adjuvant course: Two years of continuous treatment is approximately 24 pots (1,460 tablets). Planning the full course in advance, in scheduled instalments, is strongly recommended for this indication, since the benefit depends on completing the two years.
We recommend ordering your next pot before the current one is finished, allowing for international shipping transit time, so that treatment is never interrupted. Mediaid Pharmacy can arrange scheduled multi-month supply.
Monitoring and Dosage Adjustments
Full blood counts and liver function tests should be performed before starting Abemaxen, then every two weeks for the first two months, monthly for the next two months, and as clinically indicated thereafter. Neutropenia is the principal haematological concern and hepatotoxicity, seen as raised ALT and AST, is the principal biochemical one. Both are managed by dose interruption followed by resumption at a lower dose level, according to the graded severity.
Patients should be monitored for venous thromboembolism, as CDK4/6 inhibitors carry an elevated risk of deep vein thrombosis and pulmonary embolism, and for interstitial lung disease and pneumonitis, with any new or worsening cough, breathlessness, or chest discomfort investigated promptly.
One finding worth understanding in advance is a rise in serum creatinine, which commonly appears within the first month. Abemaciclib blocks the renal tubular transporters that secrete creatinine into the urine, so the blood level rises without any actual decline in kidney filtration. This effect is reversible, not a sign of kidney damage, and does not require a dose change. It is a well-recognised laboratory artefact of this medicine, but it can cause unnecessary alarm if the treating team is not expecting it.
Drug Interactions and Important Information
Abemaciclib is metabolised principally by CYP3A4, so medicines affecting this enzyme have a pronounced effect on its blood levels. Ketoconazole should not be used at all, as it is predicted to raise Abemaciclib exposure by up to sixteen-fold. With other strong CYP3A inhibitors, such as itraconazole, clarithromycin, ritonavir, and posaconazole, the Abemaxen dose must be reduced to 100mg twice daily. If a strong inhibitor is later stopped, the dose is returned to the previous level after the inhibitor has cleared.
Strong CYP3A inducers, including rifampicin, carbamazepine, phenytoin, phenobarbital, and St John’s Wort, substantially lower Abemaciclib concentrations and may reduce its effectiveness. These should be avoided and an alternative agent selected where possible. Grapefruit and grapefruit juice should be avoided throughout treatment, as they inhibit CYP3A4 in the gut wall.
Because diarrhoea is the dominant side effect, care is also needed with other medicines and supplements that loosen the stool, including magnesium-containing antacids and laxatives. Always give your oncologist a complete list of all prescription medicines, over-the-counter products, vitamins, supplements, and herbal remedies before starting Abemaxen.
Side Effects and Precautions
|
Common Side Effects Diarrhoea, usually starting in the first one to two weeks Neutropenia and leukopenia Fatigue and weakness Nausea, vomiting and abdominal pain Anaemia and thrombocytopenia Decreased appetite and weight loss Hair thinning, headache and dizziness Raised serum creatinine (a laboratory effect, not kidney injury) |
Serious Warnings and Precautions Severe diarrhoea leading to dehydration and electrolyte disturbance. Start antidiarrhoeal treatment at the first loose stool. Neutropenia with risk of serious infection. Report fever, chills, sore throat, or any sign of infection immediately. Hepatotoxicity with raised transaminases. Requires scheduled liver function monitoring. Venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Report leg swelling or pain, chest pain, or sudden breathlessness urgently. Interstitial lung disease and pneumonitis, which can be severe and may require permanent discontinuation. Embryo-foetal toxicity. Effective contraception is required during treatment and for at least three weeks after the final dose. Breastfeeding should be avoided during treatment and for at least three weeks after the final dose. Ketoconazole must not be co-administered. Other strong CYP3A inhibitors require a dose reduction. |
Who Should Use Abemaxen (Abemaciclib)?
Abemaxen is intended for adults with hormone receptor-positive, HER2-negative breast cancer. In the early-stage setting this means patients with node-positive disease at high risk of recurrence, treated after surgery in combination with endocrine therapy for two years. In advanced or metastatic disease it is used with an aromatase inhibitor as first-line therapy, with fulvestrant after progression on endocrine therapy, or as a single agent in patients already treated with both endocrine therapy and chemotherapy. It is prescribed by medical oncologists within a service capable of regular blood monitoring.
Abemaxen is not appropriate for patients with HER2-positive or hormone receptor-negative breast cancer, including triple-negative disease, where CDK4/6 inhibition offers no established benefit. Particular caution is required in patients with pre-existing liver disease, low baseline neutrophil counts, a history of thromboembolic disease or interstitial lung disease, or chronic bowel conditions that would make treatment-related diarrhoea difficult to manage. Abemaxen must not be taken during pregnancy or breastfeeding, and pre-menopausal women receiving it with fulvestrant also require ovarian suppression.
Manufacturer: Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. is an established Bangladeshi pharmaceutical manufacturer with a substantial and rapidly expanding oncology and specialty medicine portfolio. The company operates dedicated manufacturing facilities built to current Good Manufacturing Practice standards, with segregated oncology production lines and in-house analytical quality control performed on every batch for identity, assay, dissolution, and impurity profile.
Everest’s targeted therapy range spans breast, lung, colorectal, prostate, renal, and skin cancers, and includes tyrosine kinase inhibitors, ALK inhibitors, BRAF and MEK inhibitors, KRAS G12C inhibitors, and CDK4/6 inhibition. Abemaxen is available in both 150mg and 200mg strengths, covering the standard combination dose and the higher monotherapy dose used in pre-treated metastatic disease.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty oncology and targeted therapy medications sourced from Bangladesh’s leading manufacturers. We make Abemaxen (Abemaciclib) 150mg accessible to patients, oncologists, and institutional buyers worldwide through reliable worldwide shipping, with full order tracking and documentation support. Because adjuvant treatment runs for a full two years, we place particular emphasis on scheduled long-term supply planning so that patients can complete the course without gaps. Whether you are located in South Asia, the Middle East, Africa, Europe, Latin America, or beyond, our team can advise on pricing, stock availability, multi-month supply, and the documentation your country requires for personal import.
Why Choose Abemaxen (Abemaciclib) from Mediaid Pharmacy?
CDK4/6 inhibition changed the standard of care in hormone receptor-positive breast cancer, extending disease control in metastatic disease and, in the adjuvant setting, reducing the chance that an early-stage cancer ever returns. The obstacle for most patients worldwide has been cost, particularly for a two-year adjuvant course. Abemaxen delivers the same active molecule as Verzenio by Eli Lilly, at the same 150mg twice-daily dose, for a small fraction of the price. Manufactured by Everest Pharmaceuticals Ltd. to current GMP standards, supplied in a convenient two-tablet-per-day format with a clean 30-day pot, and shipped worldwide by Mediaid Pharmacy, it makes finishing the full prescribed course a realistic prospect rather than a financial impossibility. For patients with confirmed HR-positive, HER2-negative breast cancer seeking a proven, affordable, and reliably supplied Abemaciclib option, Abemaxen from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Abemaxen (Abemaciclib)
What is Abemaxen (Abemaciclib) 150mg used for?
Abemaxen (Abemaciclib) is a CDK4 and CDK6 inhibitor used to treat hormone receptor-positive, HER2-negative breast cancer. It is given after surgery alongside endocrine therapy for two years in node-positive early breast cancer at high risk of recurrence, and it is used in advanced or metastatic disease with an aromatase inhibitor, with fulvestrant, or as a single agent in patients already treated with endocrine therapy and chemotherapy.
How many Abemaxen 150mg tablets are taken per day?
Two tablets: one in the morning and one in the evening, roughly twelve hours apart and at least six hours apart, with or without food. Unlike other CDK4/6 inhibitors, Abemaxen is taken every day continuously with no scheduled rest week, so there is no cycle calendar to keep track of.
How long does one 60-tablet pot of Abemaxen 150mg last?
Exactly 30 days at two tablets daily. One pot per month, three pots for a quarter. For adjuvant treatment in early breast cancer the full two-year course is approximately 24 pots, and we recommend planning this as a scheduled supply from the outset, since the benefit depends on completing the full two years.
Why am I getting diarrhoea, and what should I do about it?
Diarrhoea is the most common side effect of Abemaciclib and usually appears within the first week or two. It is very manageable if treated straight away. Your oncologist should give you loperamide to keep at home before you start, and you should take it at the very first loose stool rather than waiting, along with drinking more fluids. Contact your oncologist the same day if it continues despite treatment, or if you have fever, dizziness, or cannot keep fluids down.
My creatinine has gone up. Is Abemaxen damaging my kidneys?
Almost certainly not. Abemaciclib blocks the transporters that move creatinine out of the blood and into the urine, so the measured level rises even though actual kidney filtration is unchanged. This typically appears in the first month, is reversible when treatment stops, and does not require a dose change. Your oncologist will still review the result in context, but this is a well-recognised effect of the medicine rather than a sign of kidney injury.
What happens if my oncologist needs to reduce my dose?
Dose reductions go from 150mg twice daily to 100mg twice daily, and if needed to 50mg twice daily. These lower doses cannot be made from 150mg tablets and the tablets must not be split, so a different strength is required. A reduction to 100mg twice daily is also needed if you must take a strong CYP3A inhibitor. Please contact Mediaid Pharmacy as soon as a dose change is being considered so we can advise on sourcing and avoid a gap in treatment.
Is Abemaxen the same as Verzenio (Abemaciclib by Eli Lilly)?
Abemaxen contains the same active pharmaceutical ingredient, Abemaciclib, in the same 150mg film-coated tablet strength as Verzenio by Eli Lilly. It is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and offered at a substantially lower cost, giving patients access to the same targeted mechanism of action without originator pricing.
Can I order Abemaxen (Abemaciclib) 150mg online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Abemaxen (Abemaciclib) 150mg and 200mg globally with worldwide shipping. A valid oncologist’s prescription is required. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email info@mediaidpharmacy.com to enquire about pricing, stock availability, long-term supply planning for adjuvant courses, and delivery to your country.
Order Abemaxen (Abemaciclib) 150mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
